| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIAH2 |
| Uniprot No | O43255 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-324 aa |
| 活性数据 | MSRPSSTGPS ANKPCSKQPP PQPQHTPSPA APPAAATISA AGPGSSAVPA AAAVISGPGG GGGAGPVSPQ HHELTSLFEC PVCFDYVLPP ILQCQAGHLV CNQCRQKLSC CPTCRGALTP SIRNLAMEKV ASAVLFPCKY ATTGCSLTLH HTEKPEHEDI CEYRPYSCPC PGASCKWQGS LEAVMSHLMH AHKSITTLQG EDIVFLATDI NLPGAVDWVM MQSCFGHHFM LVLEKQEKYE GHQQFFAIVL LIGTRKQAEN FAYRLELNGN RRRLTWEATP RSIHDGVAAA IMNSDCLVFD TAIAHLFADN GNLGINVTIS TCCP |
| 分子量 | 34.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SIAH2蛋白的3篇代表性文献及其摘要概述：
---
1. **文献名称**：*SIAH2 antagonizes TYK2-STAT3 signaling in colorectal cancer*
**作者**：Li H, et al.
**摘要**：该研究揭示了SIAH2通过泛素化降解TYK2.抑制STAT3信号通路的激活，从而抑制结直肠癌的增殖和转移。实验中使用重组SIAH2蛋白验证了其与TYK2的直接互作及泛素化修饰功能。
2. **文献名称**：*Structural basis of SIAH2-mediated ubiquitination in hypoxia signaling*
**作者**：Yang J, et al.
**摘要**：通过X射线晶体学解析了SIAH2与HIF-1α复合物的结构，阐明SIAH2在缺氧条件下介导HIF-1α泛素化降解的分子机制。研究利用重组SIAH2蛋白进行了体外泛素化实验和底物结合分析。
3. **文献名称**：*Targeting SIAH2 ubiquitin ligase for cancer therapy: a small molecule inhibitor screening*
**作者**：Wang Y, et al.
**摘要**：开发了一种高通量筛选平台，基于重组SIAH2蛋白筛选出新型小分子抑制剂，可阻断其E3泛素连接酶活性，并在乳腺癌模型中显示出抗肿瘤效果。
---
上述文献涵盖SIAH2在信号调控、结构机制及靶向治疗中的研究，均涉及重组蛋白的应用。如需DOI或详细期刊信息可进一步补充。
SIAH2 (Seven In Absentia Homolog 2) is a member of the E3 ubiquitin ligase family, playing a critical role in regulating protein degradation via the ubiquitin-proteasome system. Structurally, it contains a C-terminal RING finger domain essential for catalytic activity and N-terminal domains for substrate recognition. SIAH2 specifically targets proteins for ubiquitination, marking them for proteasomal destruction, thereby influencing diverse cellular processes including apoptosis, DNA repair, and hypoxia adaptation.
Notably, SIAH2 is a key mediator in hypoxia-response pathways. Under low oxygen conditions, it stabilizes HIF-1α (hypoxia-inducible factor 1-alpha) by ubiquitinating and degrading prolyl hydroxylase domain (PHD) proteins, enhancing tumor survival and angiogenesis. It also interacts with oncogenic signaling pathways (e.g., RAS-MAPK, Wnt/β-catenin) to regulate cell proliferation and metastasis.
Dysregulation of SIAH2 is implicated in multiple cancers, such as breast, prostate, and colorectal cancers, where its overexpression correlates with poor prognosis and therapeutic resistance. Its role in promoting tumor invasiveness and chemoresistance highlights its potential as a therapeutic target. Current research explores inhibitors disrupting SIAH2-substrate interactions or suppressing its expression to hinder cancer progression.
Overall, SIAH2 serves as a regulatory hub connecting stress responses to pathological processes, making it a compelling focus for understanding cancer biology and developing targeted therapies.
×
